RGNX · REGENXBIO Inc. · Executive Compensation
$7.53
+0.08 (+1.07%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing no longer states the doubt (first flagged May 14, 2026).
View the 10-Q filed Aug 6, 2026Market Cap
$488.50M
Shares
66.01M
Volume · Sep 30
1.79M
Avg daily vol (3M)
1.66M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Curran Simpson | President and Chief Executive Officer | $4,200,712 |
| Patrick Christmas | EVP, Chief Strategy and Legal Officer | $2,041,511 |
| Stephen Pakola | EVP, Chief Medical Officer | $1,799,546 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | Former President and CEO | $5,507,038 |
| Kenneth Mills | Former President and CEO | $5,507,038 |
| Curran Simpson | President and CEO | $4,784,543 |
| Mitchell Chan | EVP, Chief Financial Officer | $3,205,294 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,956,949 |
| Patrick Christmas | EVP, Chief Strategy and Legal Officer | $2,737,813 |
| Stephen Pakola | EVP, Chief Medical Officer | $2,696,858 |
| Vit Vasista | — | $2,226,951 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kenneth Mills | Former President and CEO | $5,916,713 |
| Kenneth T. Mills | Former President and CEO | $5,916,713 |
| Stephen Pakola | EVP, Chief Medical Officer | $3,305,985 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,985,416 |
| Curran Simpson | President and CEO | $2,950,002 |
| Former EVP | Chief Financial Officer | $2,618,404 |
| Vit Vasista | EVP, Chief Financial Officer | $2,618,404 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kenneth Mills | Former President and CEO | $5,753,713 |
| Kenneth T. Mills | Former President and CEO | $5,753,713 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,147,828 |
| Curran Simpson | President and CEO | $2,097,463 |
| Stephen Pakola | EVP, Chief Medical Officer | $1,854,615 |
| Former EVP | Chief Financial Officer | $1,852,260 |
| Vit Vasista | EVP, Chief Financial Officer | $1,852,260 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kenneth T. Mills | President and CEO | $8,622,941 |
| Kenneth Mills | President and CEO | $8,622,941 |
| Patrick Christmas | EVP, Chief Legal Officer | $3,438,888 |
| Vit Vasista | EVP, Chief Financial Officer | $3,346,165 |
| Curran Simpson | EVP, Chief Operating Officer | $3,247,167 |
| Olivier Danos | EVP, Chief Scientific Officer | $2,797,694 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Kenneth Mills | President and CEO | $7,644,087 |
| Kenneth T. Mills | President and CEO | $7,644,087 |
| Vit Vasista | EVP, Chief Financial Officer | $1,881,639 |
| Patrick Christmas | EVP, Chief Legal Officer | $1,843,929 |
| Olivier Danos | EVP, Chief Scientific Officer | $1,805,415 |
| Curran Simpson | EVP, Chief Operating Officer | $1,750,865 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Kenneth Mills | President and CEO | $6,147,269 |
| Kenneth T. Mills | President and CEO | $6,147,269 |
| Steve Pakola | Senior Vice President, Chief Medical Officer | $3,908,793 |
| Vit Vasista | EVP, Chief Financial Officer | $2,184,616 |
| Olivier Danos | EVP, Chief Scientific Officer | $1,926,420 |
| Patrick Christmas | EVP, Chief Legal Officer | $1,833,033 |
| Curran Simpson | EVP, Chief Operations and Technology Officer | $1,825,744 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Kenneth Mills | President and CEO | $4,938,199 |
| Kenneth T. Mills | President and CEO | $4,938,199 |
| Vit Vasista | Senior Vice President, Chief Financial Officer | $1,944,391 |
| Curran Simpson | Senior Vice President, Chief Operations and Technology Officer | $1,901,142 |
| Olivier Danos | Senior Vice President, Chief Scientific Officer | $1,613,769 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| A.N. "Jerry" Karabelas, Ph.D. | director | Resigned | 2026-08-25 |
| Jean Bennett, M.D., Ph.D. | director | Resigned | 2026-08-25 |
| Gregory Ciongoli | Class II director | Appointed | 2026-08-25 |
| Vittal Vasista | Executive Vice President, Chief Financial Officer and Principal Accounting Officer | Resigned | 2024-09-17 |
| Vittal Vasista | Principal Accounting Officer | Resigned | 2024-09-17 |
| Mitchell Chan | Principal Accounting Officer | Appointed | 2024-09-17 |
| Mitchell Chan | Executive Vice President, Chief Financial Officer and Principal Accounting Officer | Appointed | 2024-09-17 |
| Daniel Tassé | Lead Independent Director | Appointed | 2024-06-13 |
| Curran M. Simpson | Class I director | Appointed | 2024-06-13 |
| Curran M. Simpson | President and Chief Executive Officer | Appointed | 2024-06-13 |
| Kenneth T. Mills | Chairman of the Board | Appointed | 2024-06-13 |
| Kenneth T. Mills | President and Chief Executive Officer | Resigned | 2024-06-13 |
| Curran M. Simpson | Chief Operating Officer | Appointed | 2023-01-10 |